{"id":8511,"date":"2024-02-26T23:47:26","date_gmt":"2024-02-26T15:47:26","guid":{"rendered":"https:\/\/flcube.com\/?p=8511"},"modified":"2024-10-21T23:50:03","modified_gmt":"2024-10-21T15:50:03","slug":"simcere-pharmaceuticals-oncology-unit-raises-rmb-970-million-to-advance-cancer-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8511","title":{"rendered":"Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development"},"content":{"rendered":"\n

Simcere Pharmaceutical Group (HKG: 2096<\/a>) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company’s market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800 million, while Shenzhen Zhongshenxinchuang Investment and Apricot Capital added RMB 100 million and RMB 50 million, respectively.<\/p>\n\n\n\n

Established in December 2020, Simcere Zaiming specializes in drug development for lung cancer, gastrointestinal tumors, and gynecological tumors. The company employs a range of treatment modalities focusing on tumor immunity, cancer-driver genes, and synthetic lethality. Its pipeline includes innovative therapies developed through protein engineering, T cell and NK cell connectors, AI-assisted molecular design, protein degradation agents, and antibody-drug conjugates (ADCs).- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co.,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,1099,271,1478],"class_list":["post-8511","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-hkg-2096","tag-simcere-pharmaceutical","tag-simcere-zaiming-pharmaceutical"],"yoast_head":"\nSimcere Pharmaceutical's Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company's market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800 million, while Shenzhen Zhongshenxinchuang Investment and Apricot Capital added RMB 100 million and RMB 50 million, respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8511\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Pharmaceutical's Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8511\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-26T15:47:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-21T15:50:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8511#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8511\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development\",\"datePublished\":\"2024-02-26T15:47:26+00:00\",\"dateModified\":\"2024-10-21T15:50:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8511\"},\"wordCount\":135,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Finance\",\"HKG: 2096\",\"Simcere Pharmaceutical\",\"Simcere Zaiming Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8511#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8511\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8511\",\"name\":\"Simcere Pharmaceutical's Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-02-26T15:47:26+00:00\",\"dateModified\":\"2024-10-21T15:50:03+00:00\",\"description\":\"Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company's market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800 million, while Shenzhen Zhongshenxinchuang Investment and Apricot Capital added RMB 100 million and RMB 50 million, respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8511#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8511\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8511#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Pharmaceutical's Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development - Insight, China's Pharmaceutical Industry","description":"Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company's market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800 million, while Shenzhen Zhongshenxinchuang Investment and Apricot Capital added RMB 100 million and RMB 50 million, respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8511","og_locale":"en_US","og_type":"article","og_title":"Simcere Pharmaceutical's Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8511","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-02-26T15:47:26+00:00","article_modified_time":"2024-10-21T15:50:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8511#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8511"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development","datePublished":"2024-02-26T15:47:26+00:00","dateModified":"2024-10-21T15:50:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8511"},"wordCount":135,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Finance","HKG: 2096","Simcere Pharmaceutical","Simcere Zaiming Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8511#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8511","url":"https:\/\/flcube.com\/?p=8511","name":"Simcere Pharmaceutical's Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-02-26T15:47:26+00:00","dateModified":"2024-10-21T15:50:03+00:00","description":"Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company's market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800 million, while Shenzhen Zhongshenxinchuang Investment and Apricot Capital added RMB 100 million and RMB 50 million, respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8511#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8511"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8511#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Pharmaceutical’s Oncology Unit Raises RMB 970 Million to Advance Cancer Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8511"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8511\/revisions"}],"predecessor-version":[{"id":8512,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8511\/revisions\/8512"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}